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Abstract
Background: Epidemiological studies have examined the association between human papillomavirus (HPV) and breast
cancer, but the findings are inconclusive. This study aimed to detect the prevalence of HPV in breast cancer tissue in
patients from northeastern China and define the association between HPV and breast cancer using meta-analysis.
Methods: Polymerase chain reaction (PCR) was used to test cutaneous or mucosal HPV DNA sequence in 77
breast cancer samples and 77 corresponding adjacent normal tissues. The prevalence of HPV in breast cancer
was estimated by pooling data from 38 studies. A meta-analysis of 16 case–control studies was conducted to
investigate the association between HPV and breast cancer.
Results: We did not find HPV DNA sequence in any of the 154 tissue specimens we tested. However, our meta-analysis
revealed a HPV prevalence of 30.30 % (95 % confidence interval [CI] = 22.30–38.40 %) among breast cancer cases; most of
these involved high-risk HPV types (35.50 %, 95 % CI = 25.00–46.10 %). HPV prevalence in breast cancer varied by
geographic region, publication period, and PCR detection method. An increased risk of breast cancer was
observed in association with exposure to HPV (odds ratio [OR] = 3.24, 95 % CI = 1.59–6.57), which was influenced
by geographic region, HPV DNA source, PCR primer used, and publication period.
Conclusions: HPV, especially high-risk HPV types, may be associated with an increased risk of breast cancer, and this
association varies dramatically among geographic regions.
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Background
Breast cancer is the leading cause of cancer death in fe-
males worldwide, and its incidence and mortality rates
have been rising in many Asian countries [1]. Although
genetic susceptibility represents a risk factor for breast
cancer, the etiologic factors that determine breast cancer
risk have not been completely defined. Recently, increas-
ing evidence has indicated that some viruses, especially
human papillomavirus (HPV), may be involved in the
pathogenesis of breast cancer [2–4].
It is well known that infection with specific types of
HPV can cause cervical cancer. Additional evidence in-
dicates a role for these high-risk HPV types in anal
cancer, in up to 50 % of other anogenital cancers, and
in 25–30 % of head and neck cancers [5]. The associ-
ation of HPV with breast cancer was indicated when
Band et al. reported that HPV could immortalize nor-
mal human mammary epithelial cells and reduce their
growth factor requirements [6]. Later, HPV-16 DNA was
detected in 29.4 % of breast carcinomas by polymerase
chain reaction (PCR) [7]. Up to now the presence of HPV
DNA has been repeatedly detected in 0 to 86 % of breast
cancer [2–4, 8–40]; this large range indicates an inconsist-
ent association of HPV with breast cancer. Considering
that multiple primers are used to detect HPV DNA in
breast cancers, we hypothesized that this inconsistency
may partially result from the heterogeneity of primers
used in HPV detection. Although both type-specific
primers and general primers have been used in previ-
ous studies, most of these were designed for mucosal
HPV types [10, 11, 13, 16, 20, 21]. Thus, cutaneous
HPV types might escape detection.
* Correspondence: chuming120@163.com; weilanlan1119@163.com
Yi Zhou and Jinyuan Li are Co-first authors.
3Department of Neurosurgery, The First Affiliated Hospital, Harbin Medical
University, Harbin 150001Heilongjiang, China
2Department of Microbiology, Harbin Medical University, Immunity and
Infection, Pathogenic Biology Key Laboratory in Heilongjiang Province,
Harbin 150081Heilongjiang, China
Full list of author information is available at the end of the article
© 2015 Zhou et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Zhou et al. Infectious Agents and Cancer  (2015) 10:36 
DOI 10.1186/s13027-015-0029-6
The aim of our study was to detect any cutaneous or mu-
cosal HPV types in breast cancer using two set of primers:
MY09/11 [41], which targets mucosal HPV types, and FAP
59/64 [42], which targets cutaneous HPV types. Given the
controversy among reports regarding the relationship be-
tween HPV and breast cancer, we systematically reviewed
published studies of HPV and breast cancer to investigate
the global prevalence and type distribution of HPV in
breast cancer, to determine potential factors related to HPV
prevalence, and to examine the evidence regarding the as-
sociation of HPV infection and breast cancer risk.
Results
Molecular study
Of the 77 patients (age range: 39–74 years; mean: 49 years;
SE = 9.43) selected for our molecular study, 61 had been di-
agnosed with invasive ductal carcinomas. The clinical char-
acteristics of the breast cancer samples were shown in
Table 1. None of the patients reported a family history of
any other cancer. DNA isolated from all of these cases
underwent detection of HPV infection by PCR. All samples
were positive for β-globin gene amplification (Fig. 1a), indi-
cating that DNA was available for molecular analysis. How-
ever, no HPV DNA was detected using either mucosal
consensus primers (MY09/11) or cutaneous consensus
primers (FAP59/64) in any of the 77 breast tumor tissues
or 77 normal adjacent tissues (Fig. 1b and c). Weak bands
between 400 and 500 bp appeared in two breast cancer
samples, but the results of three extra PCR runs of the first-
cycle products or DNA from these specimens were negative
(data not shown).
The overall and type-specific prevalence of HPV in breast
cancer and factors impacting the prevalence of HPV in
breast cancer
A total of 326 published records were retrieved using
the key words mentioned previously (Fig. 2). Among
those publications, 38 studies [2–4, 7–40] were pooled
to calculate the HPV prevalence in breast cancer. The
selected studies comprised a total of 2569 breast cancer
cases, and the majority came from Asia (51.96 %) and
South America (20.32 %). The number of cases investi-
gated in each study varied from 17 to 228, and the
prevalence of HPV ranged from 0 to 86 %.
The pooled prevalence of HPV in breast cancer across
the 38 studies was 30.30 % (95 % CI = 22.30–38.40 %).
Stratified by region, Oceania yielded the highest HPV
prevalence in breast cancer, with 44.30 % (95 % CI = 33.50–
55.00 %), followed by Asia with 35.70 % (95 % CI = 20.60–
50.80 %), Europe with 32.60 % (95 % CI = 6.50–58.70 %),
South America with 14.60 % (95 % CI = 5.80–23.50 %), and
North America with 10.70 % (95 % CI = 4.40–17.00 %).
When the unconditional logit regression model was intro-
duced to compare HPV prevalence in breast cancer among
different geographic regions, the result remained consistent:
Oceanian breast cancer patients exhibited the highest HPV
prevalence, and the priority of this prevalence was statisti-
cally significant (P < 0.001) (Table 2). HPV prevalence was
found to be higher when HPV DNA was extracted from
fresh tissues (37.30 %, 95 % CI = 20.10–54.50 %) than when
HPV DNA was extracted from paraffin-embedded tissues
(27.20 %, 95 % CI = 17.90–36.40 %), but this priority of
prevalence was statistically insignificant (p = 0.08) (Table 2).
A cumulative meta-analysis was conducted to investigate
the impact of publication period on HPV prevalence in
breast cancer, and we found that the HPV detection rate
between 2007 and 2012 (22.60 %, 95 % CI = 14.40–30.70 %)
was dramatically lower than that between 1992 and 2006
(42.20 %, 95 % CI = 25.60–58.80 %) (p < 0.001) (Table 2).
PCR was the dominant method used to detect HPV in
breast cancer; it was used in 31.30 % (95 % CI = 22.60–
39.90 %) of the studies we reviewed, while HPV preva-
lence was 5.30 % (95 % CI = 2.40–8.30 %) using other
methods, such as in situ hybridization and Southern
blotting (Table 3). Multiple primers, including broad-
spectrum PCR primers, type-specific PCR primers, and a
combination of these, were used in PCR-based methods of
detecting HPV. The HPV prevalence rate was 30.00 %
(95 % CI = 18.30–41.70 %) when broad-spectrum PCR
primers were used; it was 31.90 % (95 % CI = 13.00–
50.80 %) when type-specific PCR primers were used; and
it was 35.30 % (95 % CI = 11.50 –59.00 %) when a combin-
ation of these two types of primers was used. Because
most studies dealt with invasive ductal cancer as well as
non-invasive cancer, the detection rates of HPV in inva-
sive ductal cancer were pooled, yielding HPV prevalence
of 32.90 % (95 % CI = 21.50–44.20 %) compared with non-
invasive cancer, which showed a prevalence rate of
22.00 % (95 % CI = 12.40–31.50 %) (Table 3).
Although multiple HPV types were determined in breast
cancer cases across the 38 studies in our meta-analysis, the
five most common HPV types, in decreasing order of
prevalence, were the following: HPV-16 (30.70 %; 95 %
CI = 20.50–41.00 %), HPV-33 (25.60 %; 95 % CI = 7.10–
44.00 %), HPV-11 (17.20 %; 95 % CI = 1.00–33.30 %),
HPV-18 (9.90 %; 95 % CI = 6.20–13.70 %), and HPV-6
(6.30 %; 95 % CI = 2.00–10.50 %) (Table 4). Classified
by HPV oncogenic features, the prevalence of high-risk
HPV types was 35.50 % (95 % CI = 25.00–46.10 %),
much higher than the prevalence of low-risk HPV
types, which was 11.70 % (95 % CI = 5.80–17.70 %).
The association between HPV infection and breast cancer
risk
A total of 16 case–control studies were included in our
evaluation of the association between HPV infection and
breast cancer risk (Fig. 1). Due to existing heterogeneity
(p = 0.000 for heterogeneity test, I2 = 63.9 %), a random
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Table 1 Clinical characteristics of breast cancer tissues
Patient no. Age Tumor type Tumor grade No. of LN mets % ER staining % PR staining
1 49 ILC III 18 1 0
2 55 IDC II 1 NA NA
4 43 DCIS I 0 90 70
5 44 IDC,ILC II 0 90 1
6 59 IDC NA 3 90 60
7 63 IDC II 0 90 70
8 42 DCIS II 3 90 90
9 54 IDC II 9 95 95
10 62 IDC III 0 0 0
11 61 IDC III 0 95 5
12 39 IDC II 14 80 95
13 60 IDC III 0 1 1
14 40 IDC III 13 0 3
15 57 IDC II 0 90 75
16 58 IDC II 1 95 80
17 54 IDC II 0 NA NA
18 39 IDC II 0 90 60
19 37 IDC II 5 90 80
20 36 IDC III 0 40 80
21 49 IDC III 5 80 40
22 44 IDC III 0 NA NA
23 39 IDC III 4 30 50
24 52 IDC III 0 20 80
25 46 IDC II 0 0 80
26 48 IDC II 0 90 0
27 37 IDC III 28 0 1
28 48 IDC II 10 NA NA
29 46 IDC II 0 0 0
30 38 IDC III 0 0 50
31 51 DCIS D2 0 0 80
32 52 IDC III 0 80 20
33 35 DCIS D3 0 90 70
34 38 DCIS D3 4 0 50
35 45 IDC III 0 0 1
36 64 IDC III NA NA NA
37 57 IDC II 1 90 90
38 45 IDC II 5 95 95
39 50 IDC III 5 85 90
40 43 IDC II 0
41 47 DCIS D3 0 NA NA
42 52 DCIS NA 0 85 70
43 49 IDC III 4
44 48 ILC II 10 - -
45 50 IDC II NA NA NA
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model was chosen to calculate the combined OR and its
95 % CI across the 16 studies. When these 16 studies
were pooled in the meta-analysis, results showed that
HPV infection was associated with higher risk for breast
cancer (OR =3.24, 95 % CI = 1.59–6.57, p < 0.001) (Fig. 3).
Egger’s and Begg’s tests were performed to assess the
publication bias; the results of both indicated no statis-
tical significance (p = 0.16 and 0.45, respectively).
Considering that substantial heterogeneity was observed
among the 16 studies for HPV infection and breast cancer,
the prevalence of HPV infection in breast cancer was
further evaluated by subgroup analysis. The analyzed
subgroups were defined according to the main features of
pooled studies: geographical region, DNA source, detec-
tion method (i.e., PCR primer), and publication period
(Table 5). In the subgroup of geographical regions,
between-study heterogeneity was absent (p = 0.611 for
heterogeneity test, I2 = 0.0 %) in Oceania and Europe, but
pooled OR remained the same (OR = 3.16, 95 % CI =
1.27–7.90, p < 0.001). When ORs were grouped by DNA
source, however, significantly higher risk for breast cancer
was revealed among fresh-tissue methods (OR = 7.88, 95%
CI = 3.99–15.60, p < 0.001) without between-study het-
erogeneity. Similarly, breast cancer risk was greater
Table 1 Clinical characteristics of breast cancer tissues (Continued)
46 68 IDC,MBC II 5 90 50
47 63 IDC,MBC III 0 85 85
48 53 IDC III 21 85 5
49 31 IDC III 0 0 1
50 68 IDC III 0 0 0
51 53 IDC III 0 5 3
52 69 IDC III 0 1 1
53 54 IDC II 10 90 50
54 40 IDC II 0 80 0
55 51 IDC II 0 80 50
56 43 IDC II 0 65 30
57 56 IDC II 0 70 85
58 37 IDC II 3 30 90
59 31 DCIS III 15 95 30
60 48 ILC II 0 40 60
61 74 DCIS III 4 90 15
62 53 IDC II 0 NA NA
636 40 IDC III 0 100 5
4 45 IDC III 0 50 90
65 32 IDC III 1 1 1
66 56 IDC II 8 1 0
67 55 ILC III 7 0 0
68 55 ILC II 6 80 90
69 42 IDC II 0 10 90
70 57 IDC II 0 0 90
71 44 IDC II 1 90 90
72 46 IDC II 0 0 0
73 38 IDC II 0 70 10
74 53 ILC II NA NA NA
75 47 IDC II 0 50 10
76 61 IDC III 3 0 30
77 42 IDC II 0 40 70
LN mets lymph node metastasis, % ER staining percentage of tumour cells stained for oestrogen receptor, % PR staining percentage of tumour cells stained for
progesterone receptor, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, DCIS ductal carcinoma in situ, MBC mucinous breast adenocarcinoma, NA
data not available
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with HPV infection in studies published between 1992
and 2006 (OR = 4.12, 95% CI = 2.42–7.02, p < 0.001)
compared with studies published between 2007 and
2012. HPV infection detected using broad-spectrum PCR
primers was associated with higher risk for breast cancer
(OR = 5.67, 95 % CI = 3.40–9.45, p < 0.001), while HPV in-
fection detected using combined PCR primers showed the
opposite result (OR = 0.68, 95 % CI = 0.32–1.45, p < 0.001).
Discussion
The role of HPV in breast cancer has been controversial;
thus, a PCR-based strategy as well as a meta-analysis were
conducted to investigate the association between HPV and
breast cancer. In present study, 77 breast cancer samples
and 77 adjacent normal tissues all tested negative for HPV.
However, in our meta-analysis of 38 studies from 20 coun-
tries published since 1992, we found the overall HPV
prevalence in women with breast cancer to be 30.30 %
(95 % CI = 22.30–38.40 %). Furthermore, the prevalence es-
timate varied by geographic region, publication period, and
PCR detection method. Our meta-analysis of 16 pooled
case–control studies revealed that HPV infection is associ-
ated with breast cancer risk.
In our molecular study, both cutaneous and mucosal
primers were applied to detect HPV DNA in breast tu-
mors, but no specimen was positive for HPV. Other
studies [9, 37] from China in which HPV DNA was de-
tected in breast tumors have reported similar findings,
suggesting that the HPV infection rate in breast cancer
in Chinese patients is low and that HPV infection rate
varies by geographic region. To support this idea, 38
studies [2–4, 7–40] from different regions were pooled
to calculate the prevalence of HPV infection in breast
cancer and to explore the factors impacting it.
The prevalence of HPV infection in breast cancer
ranged from 10.70 % in North America to 44.30 % in
Oceania. The geographic differences of HPV infection
rates may be related to the distinctly different cervical
cancer burdens across different continents [43]. In
1999, Hennig et al. reported that HPV-associated cer-
vical neoplasia might be the original site of HPV infec-
tion from which the virus could be transported to the
Fig. 1 Identification the quality of genomic DNA from breast cancer biopsy and detection of HPV from them by PCR. a PCR amplification of
a 268-bp fragment of human β-globin gene. b PCR amplification of a 450-bp fragment in the HPV L1 region detected using MY09/11
primers. c PCR amplification of a 478-bp fragment in the HPV L1 region detected using FAP59/64 primers. Lane M: DL 1000 DNA marker
(TaKaRa). Lane W: Sterile water (negtive control). Lane c: DNA from HPV-16 positive cervical tissues. Lane p1: pBS322/HPV16 plasmid; Lane
p2: pBS322/HPV8 plasmid; Lane p3: pBS322/HPV11 plasmid (positive control). Lanes 1–14: Breast cancer biopsy DNA
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breast [44]. We found that HPV prevalence in frozen
specimens was higher than that in paraffin-embedded
tissues, but the difference was statistically insignificant
(P = 0.08). Interestingly, the HPV detection rate of stud-
ies published between 1992 and 2006 was remarkably
higher than that of studies published between 2007 and
2012. This can be explained by the fact that the latter
generally included more breast cancer cases and that
the specificity of detection advanced over time, thus
yielding a conservative result.
Fig. 2 Flow chart of identifying the articles related to HPV and breast cancer
Table 2 HPV prevalence in breast cancer cases across region, HPV DNA source, and publication period
Variable No. of studies No. of cases Proportion(%) HPV prevalence (%) (95 % CI) P OR (95%CI) Adjusted ORa ( 95 % CI)
Total 38 2569 100 30.30(22.30–38.40) … …
Region <0.001
Oceania 3 130 5.06 44.30(33.50–55.00) Ref. Ref.
Asia 16 1335 51.96 35.70(20.60–50.80) 0.24(0.17–0.35) 0.21(0.14–0.32)
Europe 9 467 18.18 32.60(6.50–58.70) 0.17(0.11–0.27) 0.09(0.05–0.14)
South America 7 522 20.32 14.60(5.80–23.50) 0.14(0.09–0.21) 0.07(0.04–0.11)
North America 3 115 4.48 10.70(4.40–17.00) 0.14(0.07–0.28) 0.06(0.03–0.13)
HPV DNA source 0.08
Fixed tissue 24 1537 59.83 27.20(17.90–36.40) Ref. Ref.
Fresh tissue 14 1032 40.17 37.30(20.10–54.50) 0.82(0.66–1.03) 0.46(0.36–0.60)
Publication period 0
1992-2006 14 665 25.89 42.20(25.60–58.80) Ref. Ref.
2007-2012 24 1904 74.11 22.60(14.40–30.70) 0.37(0.30–0.46) 0.26(0.20–0.33)
CI confidence ratio, OR odds ratio, Ref. reference
aAdjusted for region, HPV DNA source and publication date
Zhou et al. Infectious Agents and Cancer  (2015) 10:36 Page 6 of 11
In present study, HPV prevalence in 77 breast cancer
samples and 77 adjacent normal tissues was zero, which is
lower than that estimated by the meta-analysis included in
this report. However, this is consistent with the results
showed by stratified analysis, i.e. , HPV infection rate varies
by geographic region and publication period (shown in
Table 2). The geographic differences of HPV infection rates
may be related to the distinctly different cervical cancer
burdens across different continents, since cervix is pro-
posed to be the original site of HPV infection from which
HPV could be transported to the breast. In addition, due to
the limitations of statistical software, 11 studies (references
8–12, 19–21, 27, 29, 30), as well as the present PCR-based
study, showing no HPV prevalence in breast cancer, were
not included in the pool used to estimate overall HPV
prevalence. Thus, our pooled results showed a relatively
strong combined HPV prevalence.
PCR emerged as the most effective method of detecting
HPV in breast cancer, and combining general primers and
specific primers revealed the highest HPV prevalence, due
to the diversity of HPV types that co-occur with breast
cancer. In our meta-analysis, HPV frequency in invasive
carcinomas was higher than that in non-invasive carcin-
omas, but the difference was not statistically significant,
suggesting that HPV infection may not be directly associ-
ated with the progression of breast cancer. Although mul-
tiple HPV types have been detected in breast cancer, high-
risk HPV types are more frequently detected than low-risk
HPV types. These results imply that the use of primers tar-
geting high-risk HPV will increase the detection rate of
HPV in breast cancer tissue.
Although the pooled estimate from 16 randomized con-
trolled trials revealed that HPV infection resulted in an in-
creased risk of breast cancer, the association was not strong
enough to prove that HPV plays a causal role in breast can-
cer development. To identify the definitive role of HPV in
breast cancer development, further studies are required to
investigate the temporal association between the virus and
breast cancer, the integration in the host genome, the ex-
pression of viral oncoproteins, the traits of HPV-positive
breast cancer, and the route of breast infection.
Our meta-analysis has several limitations. First, due to
the limitations of statistical software, 11 studies [8–12,
19–21, 27, 29, 30], as well as the present PCR-based
study, showing HPV prevalence in breast cancer was
zero, were not included in the pool used to estimate
overall HPV prevalence; thus, our pooled results
showed a relatively strong combined HPV prevalence.
Interestingly, of 885 cases from the 11 studies that de-
tected no HPV, 306 [9, 12, 20] cases (34.5 %) were from
Asia and in them PCR was the only method used to de-
tect HPV DNA. These results reflect those of the
current PCR-based study. Second, substantial hetero-
geneity was observed when the pooled HPV prevalence
was calculated across different continents. But uncon-
ditional logit regression revealed variables, including
geographic region and publication period, that can
only explain part of the existing heterogeneity. Third,
Table 3 HPV prevalence in breast cancer cases by detection method and histological type
Variable No. of studies No. of cases HPV prevalence (%) (95 % CI)
Detection method
PCR-based method 37 2415 31.30(22.60–39.90)
Broad-spectrum primers 20 1102 30.00(18.30–41.70)
Type-specific primers 9 481 31.90(13.00–50.80)
Combined primers 8 832 35.30(11.50–59.00)
Non-PCR-based methoda 6 466 5.30(2.40–8.30)
Histological type
IDC 27 1536 32.90(21.50–44.20)
Otherb 21 329 22.00(12.40–31.50)
CI confidence interval, PCR polymerase chain reaction, IDC invasive ductal carcinomas
aOthers included in situ hybridization and Southern blotting
bOthers included ductal carcinoma in situ, intraductal papilloma, medullary carcinoma, and mixed or unclear histological types
Table 4 Prevalence of Overall and Individual Human
Papillomavirus (HPV) Types
HPV type No. of studies No. of cases HPV prevalence (%) (95 % CI)
Total 38 2569 30.30(22.30–38.40)
High-riska 18 1169 35.50(25.00–46.10)
Low-riskb 9 616 11.70(5.80–17.70)
Presence of individual type in breast cancer cases
HPV-6 6 339 6.30(2.00–10.50)
HPV-11 4 134 17.20(1.00–33.30)
HPV-16 16 1029 30.70(20.50–41.00)
HPV-18 15 976 9.90(6.20–13.70)
HPV-31 3 334 3.00(0.00–6.10)
HPV-33 4 331 25.60(7.10–44.00)
aHigh-risk types included HPV-16, −18, −31, −33, −35, −51, −56, −58,
−59, −66,-70,-73and −82
bLow-risk types included HPV-4,-6 ,-11,-24,-27,-57,and −87
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some evidence supports the idea that some clinical features,
including age and estrogen receptors, are linked to the
HPV detection rate in breast cancer [33], and we cannot
rule out the possibility of such an effect. Detailed informa-
tion about these clinical characteristics were unavailable in
the studies used in our meta-analysis.
Although two meta-analyses [45, 46] have been pub-
lished regarding the correlation between HPV infection
and the risk of breast cancer, our meta-analysis included
a greater number of publications as well as more de-
tailed information on HPV prevalence in breast cancer.
Thus, our study has yielded more valid results.
Fig. 3 Forest plots of studies evaluating odds ratio of HPV infection to breast cancer risk
Table 5 Associations Between HPV prevalence and breast cancer Grouped by Selected Factors
Variable No. of studies Case vs Control P for
heterogeneityOR(95 % CI)a OR(95%CI)b
all 16 3.20(2.28–4.51) 3.24(1.59–6.57) 0.000
Region
Asia 9 2.81(1.84–4.28) 2.87(1.05–7.85) 0.000
South America 4 4.70(2.18–10.14) 6.46(0.62–67.88) 0.007
Europe and Oceania 3 3.16(1.27–7.90) … 0.611
DNA source
Fixed tissue 12 2.31(1.55–3.45) 2.23(0.99–5.00) 0.004
Fresh tissue 4 7.88(3.99–15.60) … 0.458
PCR primers
Broad-spectrum primers 10 5.66(3.40–9.45) … 0.566
Type-specific primers 4 3.34(1.72–6.47) 3.12(0.29–33.52) 0.002
Combined primers 2 0.68(0.32–1.45) … 0.614
Publication period
1992–2006 6 4.12(2.42–7.02) … 0.111
2007–2012 10 2.69(1.73–4.20) 3.10(1.07–8.96) 0.000
CI confidence ratio, OR odds ratio
aFixed effects model
bRandom effects model
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Conclusions
HPV infection, especially high-risk HPV types, may be
associated with an increased risk of breast cancer, and the
association varies dramatically among geographic regions.
Methods
Sample collection
A total of 77 breast cancer specimens and 77 corre-
sponding paraneoplastic breast tissues were collected
at the time of operation and were frozen immediately
at −80 °C. These samples were obtained from patients
diagnosed between February 2011 and May 2012 at the
First Affiliated Hospital of Harbin Medical University
(Harbin, China). All of the patients were women living
in northeastern China, and none had a history of cer-
vical carcinoma. Informed consent according to the cri-
teria of Harbin Medical University was obtained from
all patients, and this study was approved by the Institu-
tional Research Board of Harbin Medical University
(No. HMUIRB20120002).
DNA extraction and PCR amplification
DNA was extracted from fresh frozen breast tissues as pre-
viously described, using SDS lysis/proteinase-K digestion,
phenol/chloroform extraction, and ethanol precipitation.
The DNA quality was confirmed by the amplification of a
268-bp fragment of human β-globin gene using and
primers G073 (5′-GAAGAGCCAAG GACAGGTAC-3′)
and G074 (5′-CAACTTCATCCACGTTCACC-3′). To
avoid contamination between samples, the cutting blade
was changed after the sectioning of each sample.
DNA samples were then screened for the presence of
HPV by PCR using two sets of primers: MY09/11 and
FAP59/64. Consensus primers MY09 (5′-CGTCCMARRG-
GAWACTGATC-3′) and MY11 (5′-GCMCAGGGWCA-
TAAY AATGG-3′) amplify a 450-bp fragment in the highly
conserved region in L1 of mucosal HPV types (annealing
temperature 50 °C). Degenerated primers FAP59 (5′-
TAACWGTIGGICAYCCWTATT-3′) and FAP64 (5′-
CCWATATCWVHCATIT CICCATC-3′) can detect a
478-bp fragment in the L1 region of both mucosal and cu-
taneous HPV types (annealing temperature 55 °C). PCR
was performed in a volume of 20 μL, containing 100 ng of
extracted DNA, 1.67 mM MgCl2, 200 μM dNTPs, 0.4 μM
of each primer and 0.5 U Taq DNA polymerase (TaKaRa,
Japan), and reaction buffer (10 × PCR buffer, TaKaRa,
Japan), according to the following conditions: 5 min at 94 °
C, then 40 cycles of 5 s at 98 °C, 30s at 50 or 55 °C, and
60 s at 72 °C, followed by a 5-min extension at 72 °C in an
automated thermocycler (Eppendorf, Germany). The full
genomes of HPV-16, −11, and −8 were cloned in the
pBS322 plasmid (donated by Michelle A. Ozbun), and
HPV-18-positive cervical cancer specimens were used as
positive controls; sterile water was used as a negative
control. The PCR products were separated on 1.5 % agarose
gel (Blowest, Spain) and visualized with ethidium bromide
staining after electrophoresis.
Search strategy and selection criteria for HPV and breast
cancer
Eligible articles published from January 1989 to June 2013
were identified by an electronic PubMed search using the
MeSH terms “human,” “papillomavirus,” and “breast car-
cinoma.” Additional articles from the reference lists of re-
trieved articles were also screened. The inclusion criteria of
the studies were as follows: (1) detection of HPV in female
breast cancer; (2) full text in English; (3) independent of
other studies. The experimental results from the present
molecular study were included in the meta-analysis.
Data extraction for HPV and breast cancer
Two authors (Jinyuan Li and Lanlan Wei) independently
extracted data and reached a consensus on all issues.
Disagreements were discussed and resolved according to
the inclusion criteria and consensus. The following data
were extracted from each report: the first author, year of
publication, country of origin, ethnicity, sample size
(cases and controls), HPV prevalence, DNA source, de-
tection method, PCR primers used, histological subtypes
tested, and HPV types detected.
Statistical analysis
An epidemiological review of the overall and type-
specific HPV prevalence in breast cancer cases was
conducted. Four high-risk HPV types were identified
(HPV-16, −18, −31, −33), and two low-risk HPV types
were identified (HPV-6 and −11). A meta-analysis was
performed to explore the association between HPV in-
fection and breast cancer risk in the form of a case
(breast cancer tissues) versus control (normal breast
cancer tissues, breast tumor adjacent tissues, or benign
breast lesions) comparison. An unconditional logistic
regression model was used to compare HPV preva-
lence according to the influential parameters: HPV
DNA source, PCR primers used in detection, and pub-
lication period.
A fixed-effect model (Mantel-Haenszel method) and a
random-effect model (DerSimonian and Laird method)
were used to pool the case–control data. These two models
provide similar results when between-study heterogeneity is
absent; otherwise, the random-effect model is more appro-
priate. Between-study heterogeneity was tested using the
χ2-based Q test, and heterogeneity was considered signifi-
cant if p < 0.05. Subgroup analyses were further performed
to explore the source of the existing heterogeneity. Publica-
tion bias was evaluated using the linear regression asym-
metry tests designed by Egger et al. [47]. Analyses were
Zhou et al. Infectious Agents and Cancer  (2015) 10:36 Page 9 of 11
carried out using Stata version 11 software (StataCorp,
College Station, TX).
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